Letters
Pharmacogenetics and ethnically targeted therapies
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7506.1508-a (Published 23 June 2005) Cite this as: BMJ 2005;330:1508Racial drugs need to be put in context
- Jonathan D Kahn, assistant professor of law (jkahn01@hamline.edu)
- Hamline University School of Law, 1526 Hewitt Avenue, St Paul, MN 55104, USA
EDITOR—Rahemtulla and Bhopal focus on the heart failure drug BiDil to explore the “resurgence of the role of biology in concepts of race and ethnicity.”1 BiDil, a combination of two generic drugs (hydralazine and isosorbide dinitrate) that have been used for years to treat heart failure, is currently undergoing review by the US Food and Drug Administration …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.